Effects of SGLT2 inhibitors on cardiovascular outcomes

Diabetes and Vascular Disease Research

Volumn 9, Issue 2, 2012, Pages 117-123

  Foote, Celine ^a   Perkovic, Vlado ^a   Neal, Bruce ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cardiovascular outcomes; Clinical trials; SGLT2; Sodium glucose transporters

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EGT 0001442; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IPRAGLIFLOZIN; ISIS 388626; LIPID; LUSEOGLIFLOZIN; LX 4211; METFORMIN; MOLECULE TRANSPORT AGENT; PIOGLITAZONE; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; TRIACYLGLYCEROL; TS 071; UNCLASSIFIED DRUG;

BALANITIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOCRIT; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LOW DRUG DOSE; OUTCOME ASSESSMENT; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UROGENITAL TRACT INFECTION; VAGINITIS; WEIGHT REDUCTION;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; EVIDENCE-BASED MEDICINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861079280     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112441190     Document Type: Review

References (46)

1. Ehrenkranz JRL, Lewis NG, Kahn CR and Roth J. Phlorizin: a review. Diabetes/Metabolism Research Reviews 2005; 21: 31-38.
2. White JR. Apple trees to sodium glucose co-transporterinhibitors: a review of SGLT2 inhibition. Clinical Diabetes 2010; 28: 5-10.
3. Wright EM. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280: F10-F18.
4. Rossetti L, Smith D, Shulman GI, Papachristou D and DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-1515. (Pubitemid 17099657)
5. Santer R and Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133-141.
6. Takii H, Matsumoto K, Kometani T, Okada S and Fushiki T. Lowering effect of phenolic glycosides on the rise in postprandial glucose in mice. Biosci, Biotechnol Biochem 1997;61: 1531-1535. (Pubitemid 127472977)
7. Tsujihara K, Hongu M, Saito K, et al. Na+-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem 1999; 42:5311-5324. (Pubitemid 30036767)
8. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32: 63-71.
9. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-109.
10. Mather A and Pollock C. Glucose handling by the kidney. Kidney Int Suppl 2011: S1-S6.
11. Rahmoune H, Thompson PW, Ward JM, Smith CD, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-3434. (Pubitemid 43334332)
12. Food and Drug Administration. FDA Briefing Document NDA 202293. Dapagliflozin tablets 5 and 10mg. In: Products DoMae (ed). Silver Spring: Food and Drug Administration, 2011.
13. Grempler R. In vitro properties and in vivo effect on urinary glucose excretion of BI 10773, a novel selective SGLT2inhibitor. Diabetes 2009; 58: Abstract 521-P.
14. Liang Y. JNJ-28431754/TA-7284, an SGLT inhibitor, lowersblood glucose and reduces body weight in obese and type 2 diabetic animal models. Diabetes 2009; 58: Abstract 534-P.
15. Kipnes M. Dapagliflozin: an emerging treatment option in type 2 diabetes. Expert Opinion on Investigational Drugs 2009; 18: 327-334.
16. Inagaki N, Kondo K, Iwasaki T et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM). Diabetes 2011; 60 (Supp 1): abstract 0999-P.
17. Rosenstock J, Arbit D, Usiskin K, Capuano G and Canovatchel W. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin. American Diabetes Association, Orlando 2010: abstract77-OR.
18. Rosenstock J, Polidori D, Zhao Y, Sha S, Arbit D, Usiskin K, Capuano G and Canovatchel W. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control, lowers body weight and improves beta cell function in subjects with type 2 diabetes on background metformin (T2D) on metformin. Diabetologia 2010; 53 (SUPPL. 1): S1-S556.
19. Ferrannini E, Seman L, Seewadt-Becker E, et al. The potent and highly effective selective sodium-glucose co-transporter (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2010; 53: S1-S556.
20. Rosenstock J, Jelaska A, Seman L, Pinneti S, et al. Efficacyand safety of BI10773, a new sodium glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes 2011; 60 (SUPPL. 1): A235-A352.
21. Bailey CJ, Gross JL, Pieters A, Bastien A and List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, doubleblind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
22. Ferrannini E, Ramos SJ, Salsali A, Tang W and List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.
23. List JF and Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 2011: S20-S27.
24. List JF, Woo V, Morales E, Tang W and Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
25. Nauck M, Prato SD, Rohwedder K, Elze M and Parikh S.Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-week results of a double-blind, randomised controlled trial. Diabetologia 2010; 53: S1-S556.
26. Bailey C, Gross J, Yadav M, et al. Long-term efficacy of dapagliflozin as add-on to metformin (MET) in T2DM inadequately controlled with MET alone. Diabetes 2011; 60 (SUPPL. 1): A235-A352.
27. Nauck M, Prato SD, Rohwedder K, et al. Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results. Diabetes 2010; 60 (SUPPL. 1): A235-A352.
28. Wilding J, Woo V, Soler N, et al. Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. American Diabetes Association. Orlando, 2010.
29. Inagaki N, Kondo K, Iwasaki T, et al. Canagliflozin, anovel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM). Diabetes 2011; 60 (SUPPL. 1): A582-A643.
30. van den Heuvel LP, Assink K, Willemsen M and Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002; 111: 544-547. (Pubitemid 36075086)
31. Jabbour SA and Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucoseto improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279-1284. (Pubitemid 351977622)
32. Cohen D. Rosiglitazone: what went wrong? BMJ 2010; 341: c4848.
33. Lewis J, Ferrara A, Peng T, et al. Risk of bladder cancer among iabetic patients treated with pioglitazone. Interim report of a longitudinal cohort study. Diabetes Care 2011 34: 916-922.
34. Food and Drug Administration. Guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetictherapies to treat type 2 diabetes. In: United States Department of Health and Human Services, (ed.). 2008.
35. Turnbull F, Abraira C, Anderson R, et al. Intensive glucosecontrol and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
36. Law M, Morris J and Wald N. Use of blood pressure loweringdrugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338.
37. Wagman AS and Nuss JM. Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des 2001;7: 417-450. (Pubitemid 32409729)
38. Gaede P, Lund-Andersen H, Parving H-H and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591. (Pubitemid 351214285)
39. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.[Erratum appears in N Engl J Med 2007; 356 :1387-1388].
40. N Engl J Med 2006; 355: 2427-2443.
41. Black C, Donnelly P, McIntyre L, et al. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007: CD004654.
42. Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med 2009; 121: 94-107.
43. Kahn SE, Hull RL and Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846. (Pubitemid 46024990)
44. Woo V and Committee CDACPGS. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al. Diabetes Care 2009; 32: e34; author reply e37-38.
45. Mohler ML, He Y, Wu Z, Hwang DJ and Miller DD. Recent and emerging anti-diabetes targets. MedRes Rev 2009; 29:125-195.
46. Sicree R, Shaw J and Zimmet P. The global burden. Diabetes and impaired glucose tolerance. Baker IDI Heart and Diabetes Institute, 2010.